Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Austin Miller

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancerRobert L Hollis, Austin Miller, Heather A Lankes, et al.
The Lancet. Oncology|August 30, 2024
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroupCarien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, et al.
Journal of the National Cancer Institute|March 17, 2021
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer SurvivalLari Wenzel, Kathryn Osann, Chelsea McKinney, et al.
The New England Journal of Medicine|February 9, 2022
Survival with Cemiplimab in Recurrent Cervical CancerKrishnansu S Tewari, Bradley J Monk, Ignace Vergote, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
Journal of the National Cancer Institute|October 13, 2018
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization StudyFrank Qian, Shengfeng Wang, Jonathan Mitchell, et al.
British Journal of Cancer|June 20, 2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriersFrank Qian, Matti A Rookus, Goska Leslie, et al.
Communications Biology|October 6, 2022
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriersChristopher Hakkaart, John F Pearson, Louise Marquart, et al.
Breast Cancer Research and Treatment|November 1, 2016
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3Yosr Hamdi, Penny Soucy, Karoline B Kuchenbaeker, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 16, 2020
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variantsDaniel R Barnes, Matti A Rookus, Lesley McGuffog, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancerRobert L Hollis, Austin Miller, Heather A Lankes, et al.
The Lancet. Oncology|August 30, 2024
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroupCarien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, et al.
Journal of the National Cancer Institute|March 17, 2021
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer SurvivalLari Wenzel, Kathryn Osann, Chelsea McKinney, et al.
The New England Journal of Medicine|February 9, 2022
Survival with Cemiplimab in Recurrent Cervical CancerKrishnansu S Tewari, Bradley J Monk, Ignace Vergote, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
Journal of the National Cancer Institute|October 13, 2018
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization StudyFrank Qian, Shengfeng Wang, Jonathan Mitchell, et al.
British Journal of Cancer|June 20, 2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriersFrank Qian, Matti A Rookus, Goska Leslie, et al.
Communications Biology|October 6, 2022
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriersChristopher Hakkaart, John F Pearson, Louise Marquart, et al.
Breast Cancer Research and Treatment|November 1, 2016
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3Yosr Hamdi, Penny Soucy, Karoline B Kuchenbaeker, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 16, 2020
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variantsDaniel R Barnes, Matti A Rookus, Lesley McGuffog, et al.
Pageof 14